High-Dose Semaglutide Phase 2

Source: Diabetes, Obesity and Metabolism (2025).

Key finding: Up to 16 mg semaglutide explored.

Part of GLP1Score's 20-study clinical evidence library — the peer-reviewed research powering our GLP-1 eligibility scoring engine.

Related Reading

Semaglutide in India — Complete Guide
Semaglutide Drug Monograph (dosing, contraindications)
Who Qualifies for Semaglutide in India
Semaglutide in Adults with Prediabetes and Obesity or Overweight (STEP 10)
Oral Semaglutide 25 mg Once Daily for Obesity (OASIS 4)
GLP-1 Receptor Agonists and the Cardiovascular and Kidney Outcomes: A Meta-Analysis of Randomized Trials

Take the Free Eligibility Assessment → · Compare All 18+ Brands